Oric Pharmaceuticals, Inc. (NASDAQ:ORIC) Stock Has Consensus Target Price of $21.33 According to Brokerages

Shares of Oric Pharmaceuticals, Inc. (NASDAQ:ORIC – Get Free Report) have been assigned an average recommendation of “Moderate Buy” from the fourteen research firms that are presently covering the company, MarketBeat reports. One research analyst has rated the stock with a sell recommendation and thirteen have assigned a buy recommendation to the company. The average 1 year price objective among analysts that have covered the stock in the last year is $20.18.

Several equities analysts recently issued reports on ORIC shares. Leerink Partners initiated coverage on Oric Pharmaceuticals in a research note on Monday, October 5th. They set an “outperform” rating and a $26.00 price objective on the stock. HC Wainwright decreased their price objective on shares of Oric Pharmaceuticals from $27.00 to $20.00 and set a “buy” rating for the company in a report on Thursday. Wedbush reiterated an “outperform” rating on shares of Oric Pharmaceuticals in a research note on Tuesday. BTIG Research reissued a “buy” rating and set a $26.00 target price on shares of Oric Pharmaceuticals in a report on Tuesday. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Oric Pharmaceuticals in a report on Thursday, October 15th.

Get Our Latest Stock Report on Oric Pharmaceuticals

Insider Buying and Selling at Oric Pharmaceuticals

In related news, CFO Dominic Piscitelli sold 14,000 shares of the company’s stock in a transaction dated Tuesday, October 20th. The shares were sold at an average price of $13.53, for a total value of $189,420.00. Following the completion of the sale, the chief financial officer owned 69,828 shares of the company’s stock, valued at $944,772.84. This represents a 16.70% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 105,000 shares of company stock worth $1,432,952 in the last quarter. 5.70% of the stock is owned by insiders.

Institutional Trading of Oric Pharmaceuticals

A number of hedge funds and other institutional investors have recently made changes to their positions in ORIC. BlackRock Inc. acquired a new stake in Oric Pharmaceuticals in the second quarter worth approximately $73,904,000. Siren L.L.C. increased its position in shares of Oric Pharmaceuticals by 197.6% during the 1st quarter. Siren L.L.C. now owns 2,998,192 shares of the company’s stock valued at $37,987,000 after purchasing an additional 1,990,617 shares during the period. Algert Global LLC increased its position in shares of Oric Pharmaceuticals by 33.5% during the 3rd quarter. Algert Global LLC now owns 1,621,908 shares of the company’s stock valued at $21,847,000 after purchasing an additional 406,615 shares during the period. Dimensional Fund Advisors LP increased its position in shares of Oric Pharmaceuticals by 19.9% during the 1st quarter. Dimensional Fund Advisors LP now owns 1,471,290 shares of the company’s stock valued at $18,637,000 after purchasing an additional 244,060 shares during the period. Finally, Bank of America Corp DE increased its position in shares of Oric Pharmaceuticals by 105.5% during the 1st quarter. Bank of America Corp DE now owns 1,043,159 shares of the company’s stock valued at $13,217,000 after purchasing an additional 535,649 shares during the period. 95.05% of the stock is currently owned by institutional investors.

Oric Pharmaceuticals Stock Performance

Shares of NASDAQ ORIC opened at $7.36 on Wednesday. The stock’s 50 day moving average price is $11.08 and its two-hundred day moving average price is $10.93. Oric Pharmaceuticals has a 52-week low of $7.23 and a 52-week high of $14.68.

Oric Pharmaceuticals (NASDAQ:ORIC – Get Free Report) last issued its earnings results on Monday, November 16th. The company reported ($0.44) EPS for the quarter, missing the consensus estimate of ($0.39) by ($0.05). On average, analysts anticipate that Oric Pharmaceuticals will post -1.58 EPS for the current year.

About Oric Pharmaceuticals

(Get Free Report)

Oric Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing medicines for cancer. Its research centers on therapies intended to address treatment resistance and improve outcomes for people with tumors that have become difficult to treat. The company’s drug candidates have included ORIC-114, a targeted therapy designed to inhibit EGFR and HER2 alterations, and ORIC-944, which targets the PRC2 pathway and has been investigated for prostate cancer. These programs are investigational and are not approved medicines.

See Also

Analyst Recommendations for Oric Pharmaceuticals (NASDAQ:ORIC)

Receive News & Ratings for Oric Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oric Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.